1997
Positron Emission Tomography Measurement of Cerebral Metabolic Correlates of Yohimbine Administration in Combat-Related Posttraumatic Stress Disorder
Bremner JD, Innis RB, Ng CK, Staib LH, Salomon RM, Bronen RA, Duncan J, Southwick SM, Krystal JH, Rich D, Zubal G, Dey H, Soufer R, Charney DS. Positron Emission Tomography Measurement of Cerebral Metabolic Correlates of Yohimbine Administration in Combat-Related Posttraumatic Stress Disorder. JAMA Psychiatry 1997, 54: 246-254. PMID: 9075465, DOI: 10.1001/archpsyc.1997.01830150070011.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderAdministration of yohimbineNorepinephrine releaseHealthy subjectsHealthy age-matched control subjectsAge-matched control subjectsStress disorderDouble-blind fashionPositron emission tomography (PET) measurementsBrain metabolic responsesCerebral metabolic correlatesBrain norepinephrine releaseSymptoms of anxietyPositron emission tomographyBrain metabolismControl subjectsYohimbine administrationPreclinical studiesMetabolic correlatesCaudate nucleusPatientsYohimbineVietnam combat veteransEmission tomographyOrbitofrontal cortex
1996
Comparison of technetium-99m-HMPAO and technetium-99m-ECD cerebral SPECT images in Alzheimer's disease.
van Dyck CH, Lin CH, Smith EO, Wisniewski G, Cellar J, Robinson R, Narayan M, Bennett A, Delaney RC, Bronen RA, Hoffer PB. Comparison of technetium-99m-HMPAO and technetium-99m-ECD cerebral SPECT images in Alzheimer's disease. Journal Of Nuclear Medicine 1996, 37: 1749-55. PMID: 8917168.Peer-Reviewed Original ResearchConceptsControl subjectsAD patientsAlzheimer's diseaseAge-matched control subjectsBrain structuresBrain perfusion agentHigh diagnostic accuracyTechnetium-99mCysteinate dimerHealthy subjectsPatientsDiagnostic groupsPerfusion agentDiagnostic accuracyDiseaseSignificant differencesDiagnostic toolSPECT imagesSubjectsPurported advantagesCharacteristic analysisSignificant interactionCerebral imagesAnalysis of varianceCount density